Business
IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights
Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multipl
About this update from In8bio, Inc.
[{"type":"image","alt":"IN8bio, Inc","displaySize":"","headline":null,"caption":"IN8bio, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":149,"url":"https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LM3P9KMIYObIbb2x2kkziw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2eaff8c6754066d4f7498c1179b53d18","width":300,"height":149}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings","length":309,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":309,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multiple genetic abnormalities was treated with INB-100 and remains alive and in remission today","length":283,"tagName":"p"}]},{"val":[{"type":"text","content":"Presented new data on INB-600, a next-generation gamma-delta T cell engager (TCE) platform at the American Association for Cancer Research (AACR) 2025 Annual Meeting with potential applications across both oncology and autoimmune diseases","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued operational execution with strategic focus on meaningful data milestones including an upcoming oral presentation of INB-200 at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting","length":205,"tagName":"p"}]},{"val":[{"type":"text","content":"Raised aggregate net proceeds of approximately $4.1 million from the sale of common stock under the ATM and exercise of warrants in 1Q25","length":136,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":862,"olType":false},{"type":"text","content":"NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today repo...